Back to top
more

Fulgent Genetics (FLGT)

(Delayed Data from NSDQ)

$20.10 USD

20.10
77,988

+0.07 (0.35%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $20.10 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 252)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for FLGT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Fulgent Genetics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 424 526 451 299 28
Receivables 51 53 139 184 7
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 33 49 23 40 2
Total Current Assets 508 628 612 524 37
Net Property & Equipment 83 81 62 40 6
Investments & Advances 424 327 485 133 43
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 165 294 87 0 0
Deposits & Other Assets 55 57 33 3 0
Total Assets 1,235 1,386 1,279 700 89
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 1 6 6 0 0
Accounts Payable 15 23 20 26 2
Current Portion Long-Term Debt 0 15 15 15 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 31 25 18 8 1
Income Taxes Payable 0 0 1 53 0
Other Current Liabilities 26 19 45 27 0
Total Current Liabilities 73 88 105 130 4
Mortgages 0 0 0 0 0
Deferred Taxes/Income 8 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 21 28 8 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 102 116 113 131 6
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 502 487 502 418 146
Retained Earnings 633 801 658 151 -63
Other Equity -2 -18 6 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,133 1,270 1,166 569 83
Total Liabilities & Shareholder's Equity 1,235 1,386 1,279 700 89
Total Common Equity 1,133 1,270 1,166 569 83
Shares Outstanding 29.60 29.40 29.80 24.20 18.70
Book Value Per Share 38.29 43.19 39.12 23.53 4.43

Fiscal Year End for Fulgent Genetics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 424 468 458 504
Receivables NA 51 49 35 44
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 33 33 35 33
Total Current Assets NA 508 550 528 581
Net Property & Equipment NA 83 85 88 79
Investments & Advances NA 424 384 388 367
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 165 286 288 292
Deposits & Other Assets NA 55 53 62 58
Total Assets NA 1,235 1,358 1,355 1,377
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 1 3 5 6
Accounts Payable NA 15 16 21 22
Current Portion Long-Term Debt NA 0 0 0 15
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 31 21 22 21
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 26 22 17 18
Total Current Liabilities NA 73 61 65 82
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 8 10 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 25 26 26
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 102 97 91 108
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 502 514 506 496
Retained Earnings NA 633 761 774 786
Other Equity NA -2 -14 -17 -13
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,133 1,262 1,263 1,269
Total Liabilities & Shareholder's Equity NA 1,235 1,358 1,355 1,377
Total Common Equity 0 1,133 1,262 1,263 1,269
Shares Outstanding 29.90 29.60 29.90 29.70 29.60
Book Value Per Share 0.00 38.29 42.20 42.54 42.87